KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) EBT Margin: 2009-2025

Historic EBT Margin for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Sep 2025 value amounting to 42.22%.

  • Vertex Pharmaceuticals' EBT Margin fell 194.00% to 42.22% in Q3 2025 from the same period last year, while for Sep 2025 it was 37.95%, marking a year-over-year increase of 3550.00%. This contributed to the annual value of 2.25% for FY2024, which is 4212.00% down from last year.
  • Per Vertex Pharmaceuticals' latest filing, its EBT Margin stood at 42.22% for Q3 2025, which was down 2.44% from 43.28% recorded in Q2 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' EBT Margin peaked at 54.57% during Q3 2021, and registered a low of -128.18% during Q2 2024.
  • Over the past 3 years, Vertex Pharmaceuticals' median EBT Margin value was 43.28% (recorded in 2025), while the average stood at 26.51%.
  • Per our database at Business Quant, Vertex Pharmaceuticals' EBT Margin plummeted by 17,477bps in 2024 and then skyrocketed by 17,146bps in 2025.
  • Vertex Pharmaceuticals' EBT Margin (Quarterly) stood at 42.02% in 2021, then skyrocketed by 474bps to 46.76% in 2022, then tumbled by 118bps to 45.58% in 2023, then crashed by 655bps to 39.03% in 2024, then plummeted by 194bps to 42.22% in 2025.
  • Its EBT Margin was 42.22% in Q3 2025, compared to 43.28% in Q2 2025 and 26.37% in Q1 2025.